COT-14

CLINICAL FEATURES OF PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS

Nayuta Higa1, Hajime Yonezawa2, Hiroyuki Uchida3, Tatsuki Oyoishi1, Koji Yoshimoto1; 1Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima Japan

INTRODUCTION: Here, we discuss the presentation, histology, therapy, and outcome of central nervous system tumors in children.

METHODS: Treatment outcome and management was assessed for children diagnosed with central nervous tumors from 2007 to 2017 at Kagoshima University. RESULTS: Eight-eight patients (56 boys, 32 girls) with a mean age of 10.3 years were included in this study. Patient tumor types included: germ cell tumor (n=36), medulloblastoma (n=16); pilocytic astrocytoma (n=8); glioblastoma (n=8); ependymoma (n=6, with grade 2, 5 with grade 3); hemangioblastoma, schwannoma, and gangglioglioma (n=3 each); SEGA, pilomyxoid astrocytoma, and diffuse astrocytoma (n=2 each), and anaplastic astrocytoma, PPTID, PNET, PXA, DIA, central neurocytoma, astroblastoma, meningioma, and chordoid plexus papilloma (n=1 each). The most common patient clinical features were headache and vomiting associated with hydrocephalus. The median follow-up period was 61 months. All patients with germ cell tumors underwent adjuvant chemotherapy and radiation therapy (RT); patients with germinoma or immature teratoma were still alive, while patients with embryonal carcinoma, yolk sac tumor, or chorioniccroma had poor prognosis with a median survival of 16 months. For cases of ependymoma, three patients received ICE chemotherapy and RT, and two patients received RT alone; median survival time was 31 months. For high-grade glioma, seven patients received temozolomide and RT, and two patients received temozolomide alone; median survival time was 13 months. CONCLUSIONS: Patients with germ cell tumors had a relatively good prognosis, while patients with ependymoma or high-grade glioma had a poor prognosis. As treatment strategies for ependymoma and high-grade glioma are currently limited, it is necessary to evaluate treatment options in consideration of clinical course and quality of life, in addition to histologic and genetic findings.

COT-15

LITERATURE REVIEW ON THE DECISION-MAKING OF THE BRAIN TUMOR PATIENT

Tatsuya Kishi1, Nanami Sakurada1, Mayumi Horikawa1, Haruki Ohkubo1, Kazumi Ishii1, Yasuji Miyakota, Makoto Ohno, Masamichi Takahashi, Yoshitaka Narita1; 1National Cancer Center Hospital in Japan Nursing Division Tokyo, Japan

BACKGROUND: Patients with primary brain tumors find it difficult to make decisions during the advanced disease stage and experience decreased consciousness. It is important for patients to receive supported decision-making. Medical staff should know what to do and when to do it, but there are no clear guidelines. Therefore, we reviewed the literature for supported decision-making for primary brain tumor patients, particularly to provide information for understanding trends reported in previous research.

METHODS: On January 1, 2019, we conducted a search using keywords, such as “brain tumor” and “decision-making,” via PubMed and “Igakuchuo-zashi” in Japan. We extracted literature about treatment decision support and end-of-life care for patients with primary brain tumors. Furthermore, we studied clinical care documents for information provision. RESULTS: Upon observing 7 studies, we found: 1) about 50% of the patients want more prognostic information; 2) patients with brain tumor tend to be anxious, but they want information; 3) about half of the brain tumor patients in end-of-life care wanted more information. Upon reviewing the various studies, we found: 1) about 50% of the patients want more prognostic information; 2) patients with brain tumor tend to be anxious, but they want information; 3) about half of the brain tumor patients in end-of-life care wanted more information. Upon reviewing the various studies, we found: 1) about 50% of the patients want more prognostic information; 2) patients with brain tumor tend to be anxious, but they want information; 3) about half of the brain tumor patients in end-of-life care wanted more information. CONCLUSION: Feasibility of modern systemic therapies is not well studied for elderly patients with brain tumors. Clinical condition varies in individual elderly patients. We need prospective studies on systemic therapy in elderly patients based on an eligibility with not only chronologic age but comprehensive geriatric assessments.

COT-17

EFFECT OF BEVACIZUMAB AGAINST CYSTIC COMPONENT OF PRIMARY/METASTATIC BRAIN TUMORS

Tsunaki Yamakawa1, Motoaki Iwase1, Atsushi Yonezawa2, Akira Taguchi1, Shumpei Onishi1, Koaru Kuriyama1, Kazuhiko Sugiyama1; 1Department of Neurosurgery, Hiroshima University Hospital, Hiroshima, Japan

BACKGROUND: Bevacizumab (BEV) improves the symptoms via reducing the peritumoral edema and sometimes via reducing the size of brain tumor. However, the effect of BEV against cystic part of brain tumor has not been documented yet. In this report, we investigated the effect of BEV on the cystic component of brain tumors. MATERIALS AND METHODS: Our institutional review board approved this retrospective study. Between 2008 and 2018, 139 patients with primary or metastatic brain tumor were treated with BEV in our Hospital. We defined cystic lesions as high-intense lesion of size ≥ 1 cm or bigger on T2WI, and excluded necrotizing cysts and cystic changes in surgical resection cavity. The symptoms and images before and after administration of bevacizumab were evaluated. Changes in size of brain tumor were evaluated as follows: CR (complete response—disappearance), PR (reduction by 50% or more), MR (reduction by 25%–50%), SD (size change less than 25%), PD (increase by 25% or more). The effect of bevacizumab on tumor itself was determined according to RANO criteria. RESULTS: Of the 139 patients, 21(15.1%) brain tumors had cystic component. The best response of cyst to BEV were as follows: CR 6, PR 7, MR 4, and SD 4. The group of patients with progressively increasing cysts prior to BEV administration had significant cyst size reduction compared to stable cyst size groups at best response timing (mean 76.3% vs. 32.8%, P<0.01). Patients with cyst showed significant improvement of symptoms after the treatment with BEV compared to patients without cyst (P<0.01). However, response rate against tumor itself was not different between patients with or without cyst. Overall survival of glioblastoma patients after starting BEV was not different between tumor with or cyst and without cyst. CONCLUSION: BEV may be effective for patients who are symptomatic due to cystic enlargement.

COT-18

TWO CASES OF GliOBLASTOMA WITH ASYMPTOMATIC PULMONARY ARTERY EMBOLISM AND DEEP VEIN THROMBOSIS FROM ADMISSION TO HOSPITAL.

Yuusuke Kobayashi1, Takashi Kon1, Katsuyoshi Shimizu1, Daisuke Tanikawa1, Yusuke Satou1, Tohru Mizutani1; 1The Department of Neurosurgery,University of Showa,Tokyo, JAPAN

Patients with malignant tumors are susceptible to concurrent venous thromboembolism. We report two cases of glioblastomas that showed asymptomatic pulmonary artery embolism and deep vein thrombosis on admission. The first case was a 77-year-old male. He was referred to our clinic for a tumor found in the left temporal lobe on computed tomography scan performed when he suffered pneumonia. On admission, he had a Karmofsky performance status (KPS) score of 50 and an elevated D-dimer level (16.46 μg/ml). Pulmonary embolism and deep vein thrombosis were noted on detailed examination. Direct oral anticoagulant (DOAC) therapy resulted in the disappearance of pulmonary embolism. On biopsy, the tumor was diagnosed as glioblastoma. The patient underwent radiation therapy in combination with chemotherapy. The second case was a 71-year-old female. She developed a disorder of consciousness and was admitted to our clinic after a hypertensive area was observed on MRI. On admission, the patient had shown signs of deep vein thrombosis. Noncontrast CT scan showed a right atrial mass that was consistent with a pulmonary embolism. On the patient’s second admission, she was referred to our clinic for a tumor found in the right parietal lobe. The patient was diagnosed with glioblastoma. The patient underwent radiation therapy in combination with chemotherapy. The second case was a 71-year-old female. She developed a disorder of consciousness and was admitted to our clinic after a hypertensive area was observed on MRI. On admission, the patient had shown signs of deep vein thrombosis. Noncontrast CT scan showed a right atrial mass that was consistent with a pulmonary embolism.